Episode 31: ESMO 2025 Commentary: Prostate Cancer

https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/d2/9a/09/d29a09bb-6bb4-d3b6-1911-aad1979f4b90/mza_8029225495197491321.jpg/600x600bb.jpg

The View on GU | with Lalani and Wallis

Dr. Aly-Khan Lalani & Dr. Christopher Wallis

33 episodes

2 days ago

There is currently a lack of organic multi-disciplinary discussion on what is truly impactful to the field of genitourinary (GU) cancers. The View on GU with Lalani and Wallis is a podcast that will integrate key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians. Importantly, Lalani and Wallis will also discuss the impact of governmental approvals and funding considerations on the GU oncology treatment landscape and provide practical considerations on the management of patients on new-to-market therapies.

Medicine

Health & Fitness

RSS

All content for The View on GU | with Lalani and Wallis is the property of Dr. Aly-Khan Lalani & Dr. Christopher Wallis and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/40427888/41d07e9c28fc00dc.jpeg

Episode 31: ESMO 2025 Commentary: Prostate Cancer

The View on GU | with Lalani and Wallis

30 minutes 41 seconds

1 week ago

Episode 31: ESMO 2025 Commentary: Prostate Cancer

Live from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review the major ESMO 2025 prostate cancer studies, including ENZARAD, EMBARK, CAPItello-291, PSMAddition, and PR21. Together, they unpack their clinical impact and how evolving biomarkers, imaging, and treatment sequencing are redefining standards of care.

The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

This podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.